Prescribing extended adjuvant letrozole

Breast

Volumn 16, Issue 5, 2007, Pages 446-455

  Gelmon, K ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

Aromatase inhibitors; Breast cancer; Letrozole; Tamoxifen

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; GLUCOSAMINE; LETROZOLE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; TAMOXIFEN; VITAMIN D;

ALOPECIA; ANOREXIA; ARTHRALGIA; ARTHROPATHY; ARTICLE; BONE PAIN; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FRACTURE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; LONG TERM CARE; MYALGIA; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE; POSTOPERATIVE PERIOD; PRESCRIPTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RECURRENCE RISK; RISK BENEFIT ANALYSIS; SEXUAL DYSFUNCTION; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VAGINAL DRYNESS;

EID: 34848840321     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2007.04.002     Document Type: Article

References (51)

1. Dellapasqua S., and Castiglione-Gertsch M. The choice of systemic adjuvant therapy in receptor-positive early breast cancer. Eur J Cancer 41 (2005) 357-364
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
3. Canadian Cancer Society/National Cancer Institute of Canada. Canadian Cancer Statistics 2006. Toronto, Canada: 2006, pp 1-110. April 2006, ISSN 0835-2976 Available at: 〈http://www.cancer.ca〉 and 〈http://www.ncic.cancer.ca〉. Accessed November 27, 1006.
4. Boyle P., and Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 16 (2005) 481-488
5. Saphner T., Tormey D.C., and Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14 (1996) 2738-2746
6. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (1998) 1451-1467
7. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
8. Bryant J., Fisher B., and Dignam J. Duration of adjuvant tamoxifen therapy. J Natl Cancer Inst Monograph 30 (2001) 56-61
9. Fisher B., Dignam J., Bryant J., and Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93 (2001) 684-690
10. ® Prescribing Information 2005. Astra Zeneca Pharmaceuticals.
11. ® Prescribing Information 2005. Pfizer, Inc.
12. ® Prescribing Information 2005. Novartis.
13. Haynes B.P., Dowsett M., Miller W.R., Dixon J.M., and Bhatnagar A.S. The pharmacology of letrozole. J Steroid Biochem Mol Biol 87 (2003) 35-45
14. Dixon J.M., Renshaw L., Young O., Murray Y., et al. Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol 24 18S (2006) 15S (abstr 552)
15. Mouridsen H., Gershanovich M., Sun Y., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21 (2003) 2101-2109
16. Thürlimann B., Keshaviah A., Coates A.S., et al. for the Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
17. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 (2003) 1793-1802
18. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97 (2005) 1262-1271
19. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Thürlimann B., and Senn H.J. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16 (2005) 1569-1583
20. Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23 (2005) 619-629
21. Verma S, Pritchard K, Blais N, Gelmon K. Canadian clinical practice patterns survey of adjuvant therapies for breast cancer. 29th Annual San Antonio Breast Cancer Symposium 2006 (abstr 2106).
22. Chia S.K., Speers C.H., Bryce C.J., Hayes M.M., and Olivotto I.A. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 22 (2004) 1630-1637
23. Delozier T., Spielmann M., Janvier M., et al. Optimal duration of adjuvant tamoxifen (TAM) in early breast cancer (EBC): ten year results of a randomized trial (TAM-01) of the FNCLCC Breast Group. Breast Cancer Res Treat 94 suppl 1 (2005) S10 (abstr 14)
24. National Cancer Institute. Clinical alert: Adjuvant therapy of breast cancer-tamoxifen update. Bethesda, Md: National Institutes of Health, 1995. Available at: 〈http://www.nlm.nih.gov/databases/alerts/tamoxifen.html〉. Accessed December 1, 2006.
25. Jonat W., Howell A., Blomqvist C., et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A (1996) 404-412
26. Kaufmann M., Bajetta E., Dirix L.Y., et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 18 (2000) 1399-1411
27. Gershanovich M., Chaudri H.A., Campos D., Lurie H., Bonaventura A., and Letrozole J.M. a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol 9 (1998) 639-645
28. Dombernowsky P., Smith I., Falkson G., et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16 (1998) 453-461
29. Mann B.S., Johnson J.R., Kelly R., Sridhara R., Williams G., and Pazdur R. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. Clin Cancer Res 11 (2005) 5671-5677
30. Ingle J., Tu D., Shepherd L., Palmer M., Pater J., and Goss P. NCIC CTG MA.17: Intent-to-treat analysis (ITT) of randomized patients after a median follow up of 54 months. J Clin Oncol 24 18S (2006) 15s (abstr 549)
31. Ingle J.N., Tu D., Pater J.L., Martino S., et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 99 (2006) 295-300
32. Wardley A.M. Emerging data on optimal adjuvant endocrine therapy: Breast International Group trial 1-98/MA.17. Clin Breast Cancer 6 Suppl 2 (2006) S45-S50
33. Goss P.E., Ingle J.N., Palmer M.J., Shepherd L.E., and Tu D. Updated analysis of NCIC CTG MA.17 (letrozole vs placebo to letrozole versus placebo) post unblinding. Breast Cancer Res Treat 94 suppl 1 (2005) S10-S11 (abstr 16)
34. Baum M., Buzdar A., Cuzick J., Forbes J., Houghton J., Howell A., et al., the ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98 (2003) 1802-1810
35. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., et al. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (2004) 1081-1092 Erratum in: N Engl J Med 2004; 351:2461
36. Thurlimann B. BIG 1-98 Collaborative Group. Letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. BIG 1-98: a prospective randomized double-blind phase III study. Breast 14 suppl. 1 (2005) S3 (abstr S4)
37. Cuzick J., Powles T., Veronesi U., Forbes J., Edwards R., Ashley S., et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361 (2003) 296-300
38. Whelan T.J., Goss P.E., Ingle J.N., et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23 (2005) 6931-6940
39. ®) provides improved clinical benefit without worsening the quality of life (Qol) of postmenopausal women relative to placebo: results of the Canadian cohort in trial MA-17. Breast Cancer Res TreatS 94 suppl 1 (2005) S100 (abstr 2047)
40. Barghout V., Abetz L., Thomas S., and Arbuckle R. Impact of letrozole on quality of life in post-menopausal women with early breast cancer: does age matter?. Breast Cancer Res Treat 94 suppl 1 (2005) S97 (abstr 2040)
41. Hortobagyi G.N., Kau S.-W., Buzdar A.U., et al. What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis?. J Clin Oncol 22 14S (2004) abstr 585
42. Wengstrom Y, Aapro M, Leto di Priolo S, Cannon H, Georgiou V. Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: A European study. Breast. 2007 Apr 19. [Epub ahead of print].
43. Xu J., Bartoces M., Neale A.V., Dailey R.K., Northrup J., and Schwartz K.L. Natural history of menopause symptoms in primary care patients: a MetroNet study. J Am Board Fam Pract 18 (2005) 374-382
44. Pandit L., and Ouslander J.G. Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci 314 (1997) 228-231
45. Guthrie J.R., Dennerstein L., Taffe J.R., Lehert P., and Burger H.G. The menopausal transition: a 9-year prospective population-based study. The Melbourne Women's Midlife Health Project. Climacteric 7 (2004) 375-389
46. Presant C.A., Kelly C., Bosserman L., et al. Aromatase inhibitor (AI)-associated arthralgia (A) and bone pain (BP): frequency and characterization in clinical practice. J Clin Oncol 24 18S (2006) 334s (abstr 6137)
47. Luk C., Goss P., Pritchard K., et al. Determinants of preferences for starting extended adjuvant letrozole (L) in postmenopausal women following five years of tamoxifen. J Clin Oncol 23 16S (2005) 39s (abstr 642)
48. Ougari K., Karnon J., Delea T., et al. Cost effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. Breast Cancer Treat 101 1 (2007) 37-49
49. Karnon J., Delea T., Johnston S.R., et al. Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy. The UK perspective. Pharmacoeconomics 24 3 (2006) 237-250
50. Delea T., Karnon J., Smith R., et al. Cost effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen in postmenopausal women with early stage breast cancer. Am J Manag Care 12 7 (2006) 374-386
51. Jakesz R., Samonigg H., Greil R., et al. Extended adjuvant treatment with anastrazole: results of the Austrian Breast and Colorectal Cancer Study Group trial 6a (ABCSG-6a). Proc ASCO 23 16s (2005) abst 527